Q Fever News and Research

RSS

Sinopharm's candidate SARS-CoV-2 vaccine BBIBP-CorV shows promise in clinical trials

Researchers in China have conducted a phase 1/2 trial demonstrating the safety, tolerability, and immunogenicity of a candidate vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent responsible for the current coronavirus disease 2019 (COVID-19) pandemic.

18 Oct 2020

Objective measures reveal a higher prevalence of smell loss in COVID-19 patients

Smell loss is a frequently reported symptom of COVID-19 but reports of prevalence vary from study-to-study and range from 5% to 98%. With such a wide range of estimates, it is difficult to prioritize its importance for testing and treatment.

16 Oct 2020

FDA warns women about the risks of using NSAIDs in the second half of pregnancy

The U.S. Food and Drug Administration announced today in a Drug Safety Communication that it is requiring labeling changes for nonsteroidal anti-inflammatory drugs (NSAIDs).

15 Oct 2020

New guidance for "Long COVID" patients

“Long Covid,” which affects around 10% of patients, refers to coronavirus disease 2019 (COVID-19) that is still causing symptoms beyond 3 to 4 weeks.

15 Oct 2020

Blood purification outside the body in COVID-19 patients

Rodney Rosalia et al., in a recent medRxiv preprint research paper, study the longitudinal variation of parameters involved with systemic inflammation in critically ill COVID-19 patients upon EBP treatment.

15 Oct 2020

New position statement clarifies WHO's stance on the use of genetically modified mosquitoes

Each year, more than 700 000 people die from vector-borne diseases (VBDs) such as malaria, dengue, schistosomiasis, leishmaniasis, Chagas disease, yellow fever and Japanese encephalitis, among others.

14 Oct 2020

FDA approves Regeneron antibody drug as first treatment for Ebola virus

Today, the U.S. Food and Drug Administration approved Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn), a mixture of three monoclonal antibodies, as the first FDA-approved treatment for Zaire ebolavirus (Ebola virus) infection in adult and pediatric patients.

14 Oct 2020

Alternate primers for whole-genome SARS-CoV-2 sequencing

A new study published on the preprint server bioRxiv* in October 2020 describes the gap frequencies and positions in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genome and a set of alternative primers with a sequencing scheme to provide better genomic coverage and quality.

14 Oct 2020

AncestryDNA modeling study of 500,000 Americans sheds light on COVID-19 risk factors

Now, a new study by researchers at AncestryDNA, a company that provides DNA testing services that use modern autosomal testing technology, shows that some people are more susceptible to COVID-19 infection, and they may experience more severe outcomes, including males, the elderly, and those with comorbidities.

14 Oct 2020

First confirmed US case of SARS-CoV-2 reinfection

Of the cases of reinfections worldwide, a particular case has been reported by scientists at the Nevada Institute of Personalized Medicine, University of Nevada. A 25-year-old man from Washoe County in the United States, the hardest-hit country globally, has more than 7.85 million cases.

14 Oct 2020

Epidural analgesia during childbirth does not increase infant's risk of developing autism

The Society for Obstetric Anesthesia and Perinatology,the American Society of Anesthesiologists, the Society for Pediatric Anesthesia the American College of Obstetricians and Gynecologists and the Society for Maternal-Fetal Medicine aim to clearly reassure pregnant women that the article "Association Between Epidural Analgesia During Labor and Risk of Autism Spectrum Disorders in Offspring," a new retrospective database study published in JAMA Pediatrics on October 12th, 2020 does not provide credible scientific evidence that labor epidurals for pain relief cause autism.

13 Oct 2020

PPE may account for low SARS-CoV-2 seroprevalence in healthcare workers

A recent study published on the preprint server medRxiv in October 2020 shows that among healthcare workers, and especially among first responders, less than 1% and just over 5%, respectively, had antibodies to the virus.

13 Oct 2020

COVID-19 causes potentially damaging neurological injuries, study shows

Without directly invading the brain or nerves, the virus responsible for COVID-19 causes potentially damaging neurological injuries in about one in seven infected, a new study shows.

13 Oct 2020

Female mosquitoes can detect a combination of four different substances in blood

Mosquitoes spread diseases like malaria, dengue, and yellow fever that kill at least a half a million people each year. Now researchers are learning what humans taste like to mosquitoes, down to the individual neurons that sense blood's distinctive, delectable flavor.

13 Oct 2020

SARS-CoV-2 antibodies and COVID symptoms can last at least 3 months

Recent research published as a preprint on the medRxiv preprint server, Elizabeth T. Cirulli et al., studies the self-reported short and long-term symptoms in a large general adult population cohort.

13 Oct 2020

Scientists explain why some COVID-19 patients develop neurological symptoms

Now, a new study published on the preprint server bioRxiv sheds light on the mechanism behind brain involvement in the COVID-19 pandemic. A team of researchers at the Krembil Research Institute and the University of Toronto in Canada aimed to understand further the potential mechanisms underlying SARS-CoV-2 tropism for brain vasculature to see how infection occurs in the brain.

13 Oct 2020

Researchers identify molecular mechanisms of IFN responses in SARS-CoV-2 infection

As of October 2020, SARS-CoV-2 causes an ongoing pandemic, with more than 35 million reported cases and more than 1 million deaths worldwide. One prominent feature that distinguishes COVID-19 from SARS in terms of immune responses is the poor induction of a type I interferon (IFN) response by SARS-CoV-2 compared to SARS-CoV and influenza A virus.

12 Oct 2020

Elevated plasma ACE2 activity persists months after SARS-CoV-2 infection

Recently, researchers from the University of Melbourne and Immune Therapies Group, Burnet Institute, Melbourne, reported that downregulation of cardiac ACE2 is linked to increased plasma ACE2 activity. This study is summarized in a preprint paper published in medRxiv.

11 Oct 2020

Temporal predictors of SARS-CoV-2 antibodies

Researchers in a recent paper published as a preprint on the preprint medRxiv, study the clinical factors, the laboratory assays to streamline plasma donor selection, and the durability of nAb responses in adults.

11 Oct 2020

Pathways contributing to hypercoagulability in severe SARS‐CoV‐2 patients

In a study by researchers explored the possible mechanisms of the clotting disorder, focusing on the role of hypoxia-related activation of coagulation factors; cytokine storm, activation of neutrophils, and the release of neutrophil extracellular traps.

11 Oct 2020